Direct emissions
19,512
tCO2e
Back to search resultsEmissions
Sustainability
Scope
REPORTED REPORTED REPORTED REPORTED ESTIMATED ESTIMATED REPORTED ESTIMATED REPORTED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED 
Read the full scoring methodologyOur white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.Download the white paper (PDF)
Mycelium Score5.6 / 10A mid-pack scoreATransparencyVery HighExtensive disclosure across almost all key areas
Explore carbon emissions data for Grünenthal Pharma GmbH & Co. Kommanditgesellschaft. Mycelium helps you review reported emissions, disclosure status, Scope 1, Scope 2 and Scope 3 data, climate targets and sustainability information in one company profile.
This profile brings together available carbon emissions data for Grünenthal Pharma GmbH & Co. Kommanditgesellschaft, including reported figures, modelled estimates, disclosure documents and sustainability indicators, so you can review its emissions and compare its performance against similar companies. It is one entry in the Mycelium emissions database. Read how we source and check this data.
Emissions
Carbon emissions
Total yearly emissions across all scopes
411,719tCO2e(Market Based)(Mycelium adjusted)
- Reported by Grünenthal Pharma GmbH & Co. Kommanditgesellschaft
- 370,553 tCO₂e
- Estimated by Mycelium
- 41,166 tCO₂e
Grünenthal Pharma GmbH & Co. Kommanditgesellschaft reported 90% of the adjusted total. Mycelium estimated the remaining 10% for the categories it did not disclose. Grünenthal Pharma GmbH & Co. Kommanditgesellschaft reported 20,049 tCO₂e of Scope 3 emissions beyond its breakdown into categories. The model of the categories it did not report comes to more than that, so the adjusted total counts the model, with the reported figure inside it.
Scope 1
tCO2e
19,512
Scope 2 (Market Based)
tCO2e
540
Scope 3 total
tCO2e
391,667
Figures from page 40 of the source report
Scope 3 reported
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
Something wrong? Contribute to this dataset
See the scope breakdownProvenance
Emissions
Factors
0.200kgCO2e / $
Supplier specific emission factors (kgCO2e / $)
Modelled
Reported
UpstreamScope 1, 2 + upstream Scope 3
0.200
0.186
Total+ all Scope 3
–
0.197
Per US dollar of revenue. Mycelium models the upstream factor only.
Which figure should I use?
Estimating your own supply-chain emissions from spend with this company? Use Upstream Modelled. The GHG Protocol defines purchased-goods emissions as cradle-to-gate, which means this company's own operations plus its upstream supply chain. Any of those emissions the company has not disclosed are filled with modelled estimates, so a transparent company is not unfairly penalised against one that simply has not reported.
Looking at what the company filed itself? Use the Reported column. Total Reported also includes downstream emissions, such as the lifetime use of the products this company sells, which the GHG Protocol attributes to the users of those products rather than to customers buying goods and services.
Reported counts only emissions the company has filed itself. A blank or low Reported cell does not mean those emissions do not exist, just that the company has not disclosed them. When Upstream Reported sits close to Upstream Modelled, that is a positive signal: the company has disclosed most of its upstream emissions.
Sustainability
Snapshot
Based on reported data, retrieved with AI
- Grünenthal Pharma GmbH & Co. Kommanditgesellschaft reported 370,553 tCO₂e in 2024.
- Scope 3 accounted for 95% of reported emissions.
- Reported across 3 of 15 GHG Protocol Scope 3 categories.
- Scope 2 reported under the market based methodology.
According to available emissions disclosures, Grünenthal Pharma GmbH & Co. Kommanditgesellschaft reported total yearly emissions of 370,553 tCO₂e in 2024. Scope 3 emissions accounted for 95% of the reported footprint, indicating supply chain activity, purchased goods and services, business travel, and wider operational dependencies were the most significant contributors to the company's carbon footprint.
The company achieved a Mycelium Score of 5.6, placing it mid-pack within its sector for sustainability performance, and received a transparency score of 91.5, an exceptional result, reflecting open disclosure across nearly every key emissions metric.
Scope
breakdown
Scope 1 emissions
Direct emissions from sources the company owns or controls, such as fuel use, facilities and vehicles.
Scope 2 emissions
Indirect emissions from purchased energy, including electricity, heating and cooling.
Location based
6,265
tCO2eMarket based USED IN TOTAL
540
tCO2eScope 3 emissions
Wider value chain emissions across the 15 GHG Protocol categories, from purchased goods and business travel to investments, where reported.
Grünenthal Pharma GmbH & Co. Kommanditgesellschaft reported 20,049 tCO₂e of Scope 3 emissions beyond its breakdown into categories. Mycelium's model of the categories it did not report comes to more than that, so the estimates below replace it in the adjusted total, with the reported figure counted inside them. The reported figure is not discarded, and you can see it in the downloads below.
Cat 1
Purchased goods & services
292,859
tCO2eCat 2
Capital goods
11,681
tCO2eCat 3
Fuel & energy related activities
9,108
tCO2eCat 4
Upstream transportation & distribution
27,961
tCO2eCat 5
Waste generated in operations
1,021
tCO2eCat 6
Business travel
9,632
tCO2eCat 7
Employee commuting
3,519
tCO2eCat 8
Upstream leased assets
658
tCO2eCat 9
Downstream transportation & distribution
1,703
tCO2eCat 10
Processing of sold products
2,285
tCO2eCat 11
Use of sold products
20,191
tCO2eCat 12
End-of-life treatment of sold products
2,899
tCO2eCat 13
Downstream leased assets
979
tCO2eCat 14
Franchises
6,374
tCO2eCat 15
Investments
799
tCO2e12 values were derived via Mycelium's normalisation process rather than reported by the company. Part of the company's own Scope 3 was filed without a category, so it has no cell of its own. A cell marked “ESTIMATED” is a figure the company did not disclose, modelled by Mycelium.
Verification
Independent third parties involved in checking or preparing Grünenthal Pharma GmbH & Co. Kommanditgesellschaft's emissions data.
Independent assurance
Independently assured(limited assurance)by Deloitte GmbH Wirtschaftsprüfungsgesellschaftfor 2024
Climate targets
Science Based Targets initiative
Near-term target
Targets set (1.5°C), target year 2030
Source: Science Based Targets initiative, Companies Taking Action.
Contact Info
Website
grunenthal.comCountry
Germany
Browse carbon emissions data by industry
Jump straight into the sectors users explore most, or view all industries.
How scoring works
How the Mycelium Score is calculated
The Mycelium Score is out of 10. Up to 6.5 points reflect carbon intensity vs peers in the same NACE section (emissions normalised against revenue, log-scaled between the 5th and 95th percentile of each company's latest reporting year in that section; a section needs at least 5 companies to be benchmarked). The band above 6.5 is earned through verified data quality on a claimed profile: declaring every reporting category yourself (up to 2.0), preparation by a carbon accountant (2.0) and independently audited figures (2.0). The total is multiplied by the transparency score and capped at 10. A disclosure with an implausibly large figure (Scope 1 or 2 over 300 million tonnes, a Scope 3 figure over 2 billion tonnes or a total over 2.5 billion tonnes) is not scored until it has been checked.
A higher score means lower carbon intensity than sector peers, backed by data that's third-party verified, claimed by the company, and fully disclosed. Grünenthal Pharma GmbH & Co. Kommanditgesellschaft's score sits at the top of this page and in the score panel. Without a revenue figure to measure carbon intensity, or an industry classification to compare it within, a company has no score.
How the Transparency Score is calculated
The Transparency Score is the share of a company's estimated footprint that it reported itself, graded from A (very high) down to F (very low). Where a category is missing, Mycelium models what it would hold for a company of that size and industry and counts it as undisclosed, so an unreported category where the bulk of emissions sit hurts far more than a minor one. Unreported downstream categories (9 to 15) count at a quarter of their modelled size in this share; the carbon intensity behind the score still counts them in full. A Scope 3 total filed without a category breakdown earns very little credit for the part left unattributed, because it does not show which categories are inside it: a company can count business travel, leave purchased goods out entirely, and the total looks the same. Without a revenue figure the footprint cannot be modelled, so the company has no Transparency Score.
For Grünenthal Pharma GmbH & Co. Kommanditgesellschaft, the single biggest gap is Use of sold products (Scope 3 Category 11). Mycelium estimates it accounts for around 5% of the company's estimated footprint, yet it hasn't been disclosed. Leaving a bucket this large unreported is what's holding the transparency score down.
In total, roughly 15% of Grünenthal Pharma GmbH & Co. Kommanditgesellschaft's estimated emissions sit in categories it hasn't reported. Disclosing these would be the fastest way to raise the transparency score.
Read the full scoring methodologyOur white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.Download the white paper (PDF)Compare Grünenthal Pharma GmbH & Co. Kommanditgesellschaft with similar companies
Grünenthal Pharma GmbH & Co. Kommanditgesellschaft carbon emissions FAQs
What are Grünenthal Pharma GmbH & Co. Kommanditgesellschaft's carbon emissions?
In its 2024 reporting year, Grünenthal Pharma GmbH & Co. Kommanditgesellschaft disclosed total emissions of 370,553 tCO2e across all scopes. Including Mycelium estimates for undisclosed categories, the adjusted total is 411,719 tCO2e. Scope 3 accounted for the largest share of the reported total, around 95%.
Does Grünenthal Pharma GmbH & Co. Kommanditgesellschaft report Scope 1, Scope 2 and Scope 3 emissions?
For 2024, Grünenthal Pharma GmbH & Co. Kommanditgesellschaft's available disclosure covers Scope 1 (19,512 tCO2e), Scope 2 (540 tCO2e) and Scope 3 across 3 of the 15 GHG Protocol categories. Figures not reported by the company are shown as modelled estimates and labelled as such.
How transparent is Grünenthal Pharma GmbH & Co. Kommanditgesellschaft's emissions reporting?
Grünenthal Pharma GmbH & Co. Kommanditgesellschaft has a Mycelium transparency score of 91.5 out of 100. The score is the share of the company's estimated footprint that it reported itself, so an undisclosed category where most of its emissions sit weighs far more than a minor one.
Is Grünenthal Pharma GmbH & Co. Kommanditgesellschaft sustainable?
Mycelium measures sustainability through carbon emissions data rather than giving a yes or no verdict. Grünenthal Pharma GmbH & Co. Kommanditgesellschaft has a Mycelium Score of 5.6 out of 10, which reflects its emissions intensity against sector peers together with how transparent and well-verified its reporting is. The emissions figures, disclosure documents and climate targets on this page give the fuller picture.
Is Grünenthal Pharma GmbH & Co. Kommanditgesellschaft environmentally friendly?
Carbon emissions are one measurable part of environmental impact, and the part Mycelium tracks. Grünenthal Pharma GmbH & Co. Kommanditgesellschaft disclosed 370,553 tCO2e for 2024, and its Mycelium Score of 5.6 out of 10 shows how that performance compares with similar companies in its sector.
Learn more about our methodology and where this data comes from.